Search
SP-420
go.drugbank.com/drugs/DB16069InvestigationalSP-420 is under investigation in clinical trial NCT03801889 (SP-420 in Subjects With Transfusion-dependent Beta-thalassemia or Other Rare Anemias).
ISIS 2503
go.drugbank.com/drugs/DB16181InvestigationalISIS 2503 is under investigation in clinical trial NCT00004193 (ISIS 2503 in Treating Patients With Metastatic And/or Locally Recurrent Colorectal Cancer).
GP-100 antigen
go.drugbank.com/drugs/DB14800InvestigationalGP-100 antigen is under investigation in clinical trial NCT00006385 (Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma).
Lartesertib
go.drugbank.com/drugs/DB19045InvestigationalLartesertib is under investigation in clinical trial NCT06433219 (Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (Ddriver EOC 302)).
MYR-101
go.drugbank.com/drugs/DB17075Investigational[L43567] The FDA has granted MYR-101 Fast Track, Rare Pediatric Disease (RPD), and Orphan Drug designations for the treatment of patients with Canavan disease.[L43572]
Ciglitazone
go.drugbank.com/drugs/DB09201ExperimentalDeveloped by Takeda Pharmaceuticals in the early 1980s, it is considered the prototypical compound for the thiazolidinedione class.
Zatolmilast
go.drugbank.com/drugs/DB14790InvestigationalBPN-14770 is under investigation in clinical trial NCT02840279 (A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects).
Cobomarsen
go.drugbank.com/drugs/DB14931InvestigationalCobomarsen is under investigation in clinical trial NCT02580552 (Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL).
p-Boronophenylalanine
go.drugbank.com/drugs/DB19158Investigationalp-Boronophenylalanine is under investigation in clinical trial NCT00039572 (Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the Brain).
Cabiralizumab
go.drugbank.com/drugs/DB15082InvestigationalCabiralizumab is under investigation in clinical trial NCT03502330 (APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma).